๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Hemolysis

Sickle-cell Disease Registry of the GPOH NCT03327428n/a1 site๐Ÿ“ Heidelberg University Hospital Heidelberg Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site๐Ÿ“ Sioux Falls Sanford Health CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed โ‰ฅ3 Lines of Therapy. NCT06733610Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: universal allogeneic anti-CD19/BCMA CAR T-cells Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa NCT05285917Phase 31 site๐Ÿ“ Luanda Brown University ยท Tests: Hydroxyurea Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn NCT04218318NA1 site๐Ÿ“ Madinah Ministry of Health, Saudi Arabia ยท Tests: phototherapy Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants NCT03937817n/a1 site๐Ÿ“ Bethesda National Institute of Allergy and Infectious Diseases (NIAIโ€ฆ Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease NCT06385886n/a9 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Oakland RTI International ยท Tests: Linkage Coordinator Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia NCT05931718n/a1 site๐Ÿ“ Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico ยท Tests: cytokine essays, NGS, Fecal microbiome, Erythropoietin, Luspatercept A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease NCT06612268Phase 3175 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Phoenix Novo Nordisk A/S ยท Tests: Etavopivat, Placebo Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders NCT07104565Phase 239 sites๐Ÿ“ Glendale๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree Incyte Corporation ยท Tests: INCA000585 The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease NCT06975865Phase 363 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Clovis Sanofi ยท Tests: Rilzabrutinib, Placebo Blood Sampling for Research Related to Sickle Cell Disease NCT00542230n/a1 site๐Ÿ“ Bethesda National Institute of Diabetes and Digestive and Kidney Disโ€ฆ A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently NCT07154745Phase 320 sites๐Ÿ“ Ribeirรฃo Preto๐Ÿ“ Santo Andrรฉ๐Ÿ“ Sรฃo Paulo Regeneron Pharmaceuticals ยท Tests: Pozelimab, Cemdisiran Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients NCT06934967Phase 315 sites๐Ÿ“ Atlanta๐Ÿ“ New Brunswick๐Ÿ“ Philadelphia Novartis Pharmaceuticals ยท Tests: LNP023 Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait NCT07083531n/a1 site๐Ÿ“ Farmington UConn Health ยท Tests: Healthy volunteers without SCT, Healthy volunteers with SCT Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease NCT07566494Phase 11 site๐Ÿ“ Bethesda National Heart, Lung, and Blood Institute (NHLBI) ยท Tests: VAS-101 A Long-term Follow-up Study in Patients Who Received BEAM-101 NCT07373639n/a17 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Jacksonville Beam Therapeutics Inc. ยท Tests: Long-Term Follow-up Study of patients who received BEAM-101 A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants NCT07462780Phase 11 site๐Ÿ“ Beijing Shenzhen Kangzhe Biotechnology Co., Ltd. ยท Tests: CMS-D017 Capsule, CMS-D017 Placebo Capsule, CMS-D017 Capsule, CMS-D017 Placebo Capsule Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease NCT06941389n/a37 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Wilmington University of Rochester Natural History of Sickle Cell Disease NCT00081523n/a3 sites๐Ÿ“ Washington D.C.๐Ÿ“ Bethesda๐Ÿ“ Bethesda National Heart, Lung, and Blood Institute (NHLBI) CS-206 in Patients With Sickle Cell Disease NCT06565026EARLY Phase 11 site๐Ÿ“ Nanning CorrectSequence Therapeutics Co., Ltd ยท Tests: CS-206 Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data NCT07877727n/a4 sites๐Ÿ“ Avellino๐Ÿ“ Genova๐Ÿ“ Naples Istituto Giannina Gaslini Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study NCT07708714Phase 1, Phase 21 site๐Ÿ“ Kampala Children's Hospital Medical Center, Cincinnati ยท Tests: hydroxycarbamide Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS NCT07308574Phase 412 sites๐Ÿ“ Bunkyล City๐Ÿ“ Hirakata-shi๐Ÿ“ Iruma-Gun Alexion Pharmaceuticals, Inc. ยท Tests: Ravulizumab Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia NCT05426252Phase 1, Phase 21 site๐Ÿ“ Toronto The Hospital for Sick Children ยท Tests: Abatacept, Sirolimus mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria NCT06318143NA1 site๐Ÿ“ Abuja New York University ยท Tests: TASSH, SIM Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140Phase 39 sites๐Ÿ“ Sรฃo Paulo๐Ÿ“ Rio de Janeiro๐Ÿ“ Beijing Novartis Pharmaceuticals ยท Tests: Iptcaopan 200 mg Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study NCT05089227Phase 21 site๐Ÿ“ Dijon Centre Hospitalier Universitaire Dijon ยท Tests: treatment "intervention", treatment "standard", biological assessment
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy